Angitia Biopharmaceuticals

Angitia

This clinical-stage biotechnology company develops biologic therapies for patients with serious musculoskeletal diseases, including osteoporosis, osteogenesis imperfecta and spinal fusion conditions.

Skeletalis

This biotechnology company develops bone-targeted small-molecule therapies for patients with osteoporosis and other musculoskeletal diseases.

Mereo BioPharma

The company develops clinical-stage therapies for patients with rare diseases, including osteogenesis imperfecta and alpha-1 antitrypsin deficiency-associated lung disease.

BOOST Pharma

This company develops an off-the-shelf therapy to treat children born with severe osteogenesis imperfecta, also known as brittle bone disease.

Engage Therapeutics

This biopharmaceutical company develops medicines for patients living with severe neurological and autoimmune conditions, including epilepsy, psoriasis and osteoporosis.

Edgewise

This biopharmaceutical company develops oral small molecule therapies to treat patients with rare skeletal and cardiac muscle diseases.

Clementia

Clementia develops drugs for rare bone diseases, including fibrodysplasia ossificans progressiva, for patients with these life-altering conditions.

Attovia Therapeutics

The company develops biparatopic biologics to treat patients with immune-mediated diseases and cancer through a modular protein design platform.